Sensorion: 2024 Review and Outlook for 2025

On March 14, 2025, Sensorion reported its results for fiscal year 2024, marking significant progress in its clinical projects. The company has completed enrollment for the first cohort of its Audiogene trial with SENS-501 and expects to report new data in the first half of 2025.

Meanwhile, SENS-401 met its primary endpoints in the Phase 2a study for cochlear implants. As for the program aimed at countering cisplatin-induced ototoxicity, recruitment is complete, and results are expected by the end of 2025.

Thanks to capital increases, the company's cash position reached €77 million, securing financing until 2026. The company has strengthened its team and institutional partners to support its continued growth.